# MoonRISe-3 (NCT06919965)

> A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06919965
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Non-Muscle Invasive Bladder Neoplasms
- Interventions: TAR-210; Mitomycin C; Gemcitabine
- Enrollment: 220
- Primary outcome: Disease-free Survival (DFS)

## Commentary we found

- YouTube: 6
- Podcasts: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=moonrise-3-nct06919965

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06919965", "email": "<work email>"}; the inbox owner confirms by the emailed link.